spacer
home > pmps > winter 2019 > a closer look at child-resistant packaging
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A Closer Look at Child-Resistant Packaging

Child-resistant (CR) packaging is that which is designed or constructed to be significantly difficult for young children to open or gain access to the contents within a reasonable time and not difficult for normal adults to use properly. Child-resistant packaging can be as well reclosable as non-reclosable, and the child-proof fastenings can also be classified according to their type:

• The closure is incomprehensive for children, because two movements are needed at the same time (for instance, push-turn caps and squeeze-turn caps)
• The closure is unreachable for children, because, for example, it is too large for a child’s hand
• The closure must be opened with a force too strong for a child

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Cedric Dujardin is an Analyst Consultant of child resistant packaging at the Belgian Packaging Institute (IBE-BVI).
spacer
Cedric Dujardin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Protagen Protein Services expands analytical Service Spectrum in Biosimilar Development Support

Heilbronn/Dortmund February 2019: The success or failure of the development of a biopharmaceutical product is also governed by protein stability. Protein stability is considered a critical parameter during manufacturing, production, formulation, long term storage, efficacy, and delivery to patients. To meet our customer demands now and in the future, PPS always invests in new analytical technique and recently added a new Differential Scanning Calorimetry (DSC) device.
More info >>

White Papers

Challenges of Analytical Method Transfer in the Pharmaceutical Industry

RSSL

The development and validation of suitable analytical methods is a critical part of the overall drug-development life-cycle. For the majority of products, particularly those that are clinically successful, the transfer of the analytical method between laboratories will be required. This process is designed to verify that a given laboratory is capable of performing a test method for its intended purpose. This can be performed either internally (at the same company), or, with the on-going increasing trend in outsourcing, to an external Contract Research or Development organisation (CRO or CDO).
More info >>

 
Industry Events

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

13-14 May 2019, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019. The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement